On December 4th, 2024, Midtown Manhattan woke up to a shocking act of violence. Brian Thompson, the CEO of UnitedHealthcare, was gunned down in the early hours of the morning. The bullets reportedly carried a chilling inscription: “Deny, depose, defend.” A phrase widely associated with tactics used by insurance companies to delay or reject claims.
The event was tragic. But what stunned observers even more was the public reaction that followed.
Instead of universal sympathy, the incident sparked a nationwide conversation about the American healthcare system. Across social media, news outlets, and public forums, millions of Americans began sharing stories of denied claims, crushing medical bills, delayed treatments, and bureaucratic battles with insurers. The outrage was not just directed at a single company—it was aimed at the entire system.
And the anger is not difficult to understand.
The United States spends more on healthcare than any country in the world. Nearly $5 trillion a year, representing close to 18% of the entire economy, flows into hospitals, insurance companies, pharmaceutical firms, and medical providers. Yet despite this massive spending, Americans visit doctors less frequently than people in other wealthy nations and live shorter lives on average.
In fact, when compared with other high-income countries, the United States consistently ranks near the bottom in health outcomes and access to care.
How can the most expensive healthcare system in the world produce such disappointing results?
To answer that question, we have to look beyond individual stories of denied claims or surprise bills. The real problem lies deeper—in the structure of the system itself. American healthcare is not a single institution but a complex network of insurers, hospitals, doctors, pharmaceutical companies, and regulators, each operating under its own incentives.
Individually, these actors behave rationally. Collectively, they produce a system that is extraordinarily expensive, administratively complex, and often hostile to the very patients it is supposed to serve.
To understand why US healthcare feels so broken, we need to break the system down into its core components: insurance, healthcare providers, and pharmaceutical companies—and examine how the incentives inside each of these sectors shape the outcomes Americans experience today.
The $5 Trillion Healthcare System That Delivers Poor Outcomes
The Most Expensive Healthcare System in the World
The United States does not just spend more on healthcare than other countries—it spends dramatically more.
Every year, Americans collectively spend nearly $5 trillion on healthcare. That amount represents roughly 18% of the entire US economy, a share far higher than any other developed nation. For comparison, most wealthy countries spend between 9% and 12% of their GDP on healthcare.
On a per-person basis, the gap becomes even more striking. Americans spend thousands of dollars more per year on healthcare than citizens of countries like Germany, Canada, France, or the United Kingdom.
In theory, such enormous spending should translate into the most advanced, accessible, and effective healthcare system in the world. If money alone determined outcomes, Americans should enjoy the longest life expectancies, the best disease treatment rates, and the most accessible care anywhere on the planet.
But that is not what happens.
Spending More While Getting Less Care
Despite record-breaking healthcare spending, Americans actually use healthcare services less frequently than people in many other developed countries.
On average, Americans see doctors about 50% less often than patients in comparable wealthy nations. This is not because Americans are healthier. In fact, many key health indicators suggest the opposite.
The reason is simple: cost.
Even for insured patients, healthcare in the United States often comes with significant out-of-pocket expenses, including deductibles, copayments, and uncovered services. As a result, millions of Americans delay or avoid medical treatment altogether.
Surveys consistently show that nearly 40% of Americans have either postponed medical care or know someone who has done so because of cost. For many families, visiting a doctor is no longer a routine part of healthcare—it is a financial calculation.
And when people delay treatment, small health issues often turn into larger and more expensive problems.
The Outcome Gap Between the US and Other Developed Countries
Given the enormous spending and advanced technology present in American medicine, many people assume that the United States must still achieve excellent health outcomes.
But the data tells a different story.
Among high-income nations, the United States consistently ranks near the bottom in measures of healthcare performance, including access to care, preventable deaths, and overall health outcomes. One of the most telling statistics is life expectancy.
Despite spending more than any other country, Americans live roughly three years less on average than citizens of comparable wealthy nations.
In other words, the United States pays more for healthcare than anyone else—and yet receives worse results.
This disconnect between cost and outcomes is the central paradox of American healthcare. It suggests that the problem is not simply how much the country spends, but how the system itself is structured.
To understand why costs keep rising without improving health outcomes, we have to examine the first major pillar of the system: health insurance.
Insurance: The Administrative Monster
Why Insurance Choice Creates Complexity Instead of Efficiency
At first glance, the American health insurance system appears to offer something valuable: choice.
Unlike many countries where the government operates a single national healthcare system, Americans typically choose from multiple private insurers. These plans may come through employers, government programs like Medicare and Medicaid, or individual marketplace policies.
In theory, this competitive structure should benefit consumers. Multiple insurers competing for customers should drive innovation, reduce costs, and improve service quality.
But in healthcare, this supposed advantage creates an entirely different outcome.
Every insurance company operates with its own rules, networks, billing systems, authorization requirements, reimbursement formulas, and pharmacy arrangements. Doctors and hospitals must navigate different billing codes, approval procedures, documentation requirements, and payment systems depending on which insurer a patient has.
Instead of creating efficiency, this fragmented structure produces an extraordinary amount of administrative complexity.
Healthcare providers spend enormous amounts of time managing paperwork, negotiating reimbursements, and complying with insurer requirements—activities that have nothing to do with actually treating patients.
The Administrative Burden That Consumes Healthcare Spending
The administrative costs generated by this complex insurance structure are staggering.
According to the American Hospital Association, roughly 40% of hospital expenses in the United States are related to administrative functions, not medical care. That includes billing departments, insurance verification staff, compliance specialists, and countless other roles designed solely to navigate the insurance system.
When researchers compare healthcare spending across developed countries, they find that roughly 30% of the cost difference between the US and other nations comes directly from administrative overhead.
In other words, a massive portion of American healthcare spending is not paying for doctors, treatments, or medicines. It is paying for the bureaucracy required to manage a fragmented insurance system.
For physicians and hospitals, this administrative burden is not optional. It is the price of operating in a system where every insurer plays by different rules.
But the complexity of insurance does more than inflate costs—it also shapes how care is delivered.
Claim Denials and the Incentive to Reject Care
Insurance companies exist to manage financial risk, and one of the most powerful tools they use to control costs is the denial of claims.
Across the United States, health insurers reject roughly 16% of all medical claims. Some companies deny claims at even higher rates. Reports suggest that companies like UnitedHealthcare and Medica deny more than a quarter of claims submitted for reimbursement.
For patients, a denied claim can mean that a recommended treatment is no longer covered. At that point, individuals face a difficult decision: pay for the treatment out of pocket or forgo care entirely.
The consequences can be severe. Medical debt remains one of the leading causes of financial distress in the United States, and estimates suggest that around two-thirds of personal bankruptcies are connected to medical expenses.
Insurance companies argue that denials are necessary to prevent unnecessary treatments and control costs. And in some cases, that may be true.
But the incentives within the system create a powerful reason for insurers to deny as many claims as legally possible.
Most patients never challenge those denials.
The Hidden Damage of Prior Authorizations
Another powerful tool used by insurers is prior authorization.
Under this system, doctors must obtain approval from an insurance company before certain treatments, tests, or procedures can be performed. In theory, this requirement ensures that care is medically necessary and prevents unnecessary spending.
In practice, it often introduces dangerous delays.
Physicians frequently report spending hours or even days navigating approval processes for treatments they believe are urgently needed. These approvals are typically reviewed by physicians working for the insurance company, but those reviewers are not always specialists in the relevant field.
In some cases, the results can be devastating. Surveys have found that significant numbers of doctors report patients suffering emergency hospitalizations or permanent complications due to delays caused by prior authorization requirements.
For patients facing serious illnesses, these delays can mean the difference between timely treatment and irreversible harm.
The troubling reality is that many insurance denials are never challenged. Appealing a claim requires time, documentation, and persistence—resources that many patients simply do not have while dealing with illness.
And when appeals are filed, a striking number of denials are eventually overturned.
Which raises a troubling question: if so many rejected claims are later approved, why were they denied in the first place?
The answer lies in incentives. In a system where insurers benefit financially from rejecting claims—and where only a tiny fraction of those decisions are appealed—denying care becomes a rational business strategy.
And insurance companies are not the only actors whose incentives shape the system.
Market Concentration and the Power of Insurance Giants
How Insurance Consolidation Raises Prices
If the American health insurance market were truly competitive, the presence of multiple insurers might lead to lower premiums and better service. But over the past several decades, the industry has steadily moved in the opposite direction.
Instead of many companies competing aggressively for customers, the market has become increasingly concentrated.
Today, a handful of large insurers dominate the American healthcare landscape. In fact, studies show that 73% of commercial insurance markets, 71% of Medicare Advantage markets, and 90% of Affordable Care Act marketplaces are considered highly concentrated.
In practical terms, this means that in many regions of the United States, only one or two major insurers control most of the market.
In theory, larger insurers should be able to negotiate lower prices with hospitals and pharmaceutical companies due to their size. If those savings were passed along to consumers, consolidation could potentially reduce healthcare costs.
But that is rarely what happens.
Instead, as insurers gain more market power, they often increase premiums and expand profits, while patients see little benefit from the added scale.
Why Competition Rarely Lowers Healthcare Costs
Multiple academic studies examining health insurance mergers have found a consistent pattern: when insurance companies consolidate, premiums tend to rise.
For example, mergers involving major insurers such as Aetna, Prudential, UnitedHealth, and Sierra have been analyzed over the years. The results repeatedly show that consolidation leads to higher prices for consumers, not lower ones.
The logic behind this outcome is straightforward.
When only a few companies dominate a market, competition weakens. Consumers have fewer alternatives, employers have less bargaining power, and new entrants face enormous barriers to entry.
Launching a new insurance company requires navigating strict regulations, building large provider networks, developing complex billing systems, and accumulating enough capital to manage risk across thousands or millions of patients.
As a result, the existing giants face very little realistic competition.
This concentration allows insurers to maintain high premiums while limiting the pressure to improve service or reduce costs.
Vertical Integration and the Expansion of Insurance Power
In recent years, major insurance companies have taken their influence even further by vertically integrating into other parts of the healthcare system.
Rather than simply acting as intermediaries that pay for care, insurers have begun acquiring or building businesses across the entire healthcare ecosystem. These include physician groups, clinics, pharmacy benefit managers, and even hospitals.
One of the most prominent examples is UnitedHealth Group. Through its healthcare services division, the company employs tens of thousands of physicians and maintains commercial relationships with tens of thousands more, giving it influence over a significant share of American medical care.
This type of vertical integration allows insurers to capture revenue at multiple stages of the healthcare process—from insurance premiums to medical services and pharmaceutical distribution.
While companies often argue that integration improves coordination and efficiency, critics warn that it can also concentrate enormous power in the hands of a few corporate players.
When insurers control both the financing of care and the providers delivering it, the risk grows that decisions will prioritize corporate profitability rather than patient outcomes.
The result is a healthcare landscape where a small number of companies exert enormous influence over how care is delivered, priced, and approved.
But insurance companies are only one part of the system.
To fully understand why healthcare costs are so high, we also have to examine the people delivering that care—and the structural forces shaping their profession.
Doctors and the Artificial Shortage of Physicians
How the US Created a Physician Supply Problem
Doctors are often seen as the heroes of the healthcare system—highly trained professionals dedicated to saving lives and improving patient health. And in many cases, that reputation is well deserved.
But the structure of the American healthcare system has also created a powerful economic dynamic around the medical profession itself: a persistent shortage of physicians.
Compared to other developed countries, the United States has significantly fewer practicing doctors relative to its population. On average, the US has roughly 2.6 physicians per 1,000 people, while the average across developed OECD countries is closer to 3.7 physicians per 1,000 people.
That gap may seem small at first glance, but across a population of hundreds of millions, it translates into tens of thousands of missing doctors.
A limited supply of physicians has predictable economic consequences. When demand for medical services continues to rise—due to population growth, aging demographics, and chronic disease—but the number of doctors grows slowly, the value of each physician increases dramatically.
The result is higher compensation, longer wait times, and reduced access to care.
The Role of the American Medical Association
One of the major forces shaping this shortage is the structure of medical education in the United States.
For decades, the number of new physicians entering the workforce was effectively capped by limits on medical school enrollment and residency positions, many of which were influenced by lobbying efforts from powerful professional organizations.
Historically, the American Medical Association (AMA) and related institutions expressed concern about a potential oversupply of doctors. In response, policies were supported that reduced medical school capacity and limited federal funding for residency programs.
These restrictions had long-term consequences.
Between 1980 and 2005, the number of medical school graduates in the United States remained almost unchanged—even though the country’s population grew by roughly 30% during the same period.
In effect, the system trained the same number of doctors for a dramatically larger population.
The result was predictable: a growing shortage of physicians that persists today.
The Consequences of Too Few Doctors
When the supply of doctors remains limited, the effects ripple across the entire healthcare system.
First, physician salaries rise significantly. US doctors are among the highest paid in the world, often earning substantially more than their counterparts in other developed countries.
Second, patients face longer wait times and reduced access to care, particularly in rural or underserved areas where physician shortages are most severe.
And third, the scarcity of doctors strengthens the bargaining power of large hospital systems and healthcare corporations that employ them.
In other words, the shortage of physicians does not just affect patient access—it also reshapes the economics of healthcare delivery itself.
But doctors are no longer the independent professionals they once were.
Over the past two decades, the structure of medical practice in the United States has undergone a dramatic transformation, as hospitals and investment firms have increasingly consolidated control over healthcare providers.
Hospital Consolidation and the Rise of Corporate Medicine
Why Independent Practices Are Disappearing
For much of the twentieth century, the typical American doctor worked in a small private practice. Physicians owned their clinics, made their own treatment decisions, and handled their own business operations.
That model has been steadily disappearing.
Today, roughly three out of every four doctors in the United States work for a hospital system, corporate medical group, or large healthcare organization rather than running an independent practice. The shift has accelerated dramatically over the past two decades.
One of the primary reasons is the growing administrative burden of operating in the American healthcare system. Independent doctors must deal with insurance billing requirements, compliance regulations, electronic medical records systems, coding rules, legal risk, and negotiation with insurers.
Managing all of this complexity requires staff, technology, and expertise—costs that smaller practices often struggle to afford.
Joining a larger hospital network or corporate medical group allows physicians to outsource many of these administrative tasks. In return, they give up a significant degree of independence.
This dynamic has fueled a wave of consolidation across the healthcare industry.
Private Equity’s Entry Into Healthcare
Hospitals and medical practices are no longer just part of the healthcare system—they have increasingly become investment opportunities.
Private equity firms, which specialize in buying companies and restructuring them for profit, have moved aggressively into healthcare over the past two decades. They have acquired physician groups, specialty clinics, hospital systems, and nursing homes across the country.
From an investor’s perspective, healthcare can appear extremely attractive.
Patients rarely have the option to delay critical care indefinitely. Demand for healthcare services is relatively stable, and insurance coverage often guarantees payment. These characteristics make healthcare businesses appear relatively resistant to economic downturns.
Private equity firms often claim that their involvement improves efficiency by streamlining operations, reducing administrative costs, and expanding access to capital.
In theory, those efficiencies could lower costs for patients.
In practice, the results often look very different.
The Profit Model of Healthcare Consolidation
When healthcare providers consolidate—whether through hospital mergers or private equity acquisitions—they gain market power.
That power allows them to negotiate higher reimbursement rates from insurers and charge more for services. In many regions, consolidation has dramatically reduced the number of competing hospitals or physician groups available to patients.
Research shows that when private equity firms control a significant share of a local healthcare market, prices tend to rise substantially. In some specialties, studies have observed price increases of more than 15% after private equity consolidation.
A striking example occurred in the Denver area, where a company called US Anesthesia Partners acquired a large share of local anesthesiology practices. With limited competition remaining, the company was able to charge reimbursement rates 30% to 40% higher than competing providers.
These price increases occur even when the underlying cost of providing care does not change.
Even more troubling, some studies suggest that consolidation can actually reduce the quality of care.
Research examining private equity ownership of nursing homes found that mortality rates increased after acquisitions. Other studies have linked hospital acquisitions to higher complication rates and increased infection risks.
The explanation is not mysterious.
When healthcare providers are owned by investors carrying significant debt obligations, there is constant pressure to increase revenue and reduce costs. Cutting staffing levels, accelerating patient throughput, and reducing certain services can improve financial performance—but may also affect patient care.
And while for-profit hospitals often attract the most criticism, they are not the only institutions behaving like large corporations.
Even organizations officially classified as nonprofit hospitals have increasingly adopted the compensation structures and executive incentives of the corporate world.
Nonprofit Hospitals and Executive Compensation
When Nonprofit Healthcare Starts Acting Like Big Business
Many Americans assume that nonprofit hospitals operate differently from for-profit healthcare corporations. In theory, nonprofit institutions exist to serve their communities rather than generate profits for shareholders.
Because of this mission, nonprofit hospitals receive significant benefits. They are typically exempt from certain taxes and often receive public support in exchange for providing community services, charity care, and accessible medical treatment.
But in practice, the line between nonprofit and corporate healthcare has become increasingly blurred.
Many nonprofit hospital systems now operate on multi-billion-dollar budgets, manage extensive networks of clinics and specialty centers, and compete aggressively with other hospital groups for market share. They employ large executive teams, expand through acquisitions, and invest heavily in facilities, technology, and marketing.
In many ways, these organizations behave much like large corporations—even though they maintain nonprofit status.
The Disconnect Between Mission and Incentives
One of the clearest signs of this shift can be seen in executive compensation.
At several major nonprofit hospital systems, top executives receive compensation packages that rival those of leaders in the private corporate world. In some cases, hospital CEOs earn millions of dollars annually.
For example, the former CEO of UPMC, one of the largest nonprofit hospital systems in the United States, reportedly earned nearly $13 million in compensation in a single year.
For critics, this raises an uncomfortable question: if nonprofit hospitals exist primarily to serve patients and communities, why do their leaders receive compensation on the scale of major corporate executives?
Supporters argue that managing large healthcare systems requires highly skilled leadership, and competitive salaries are necessary to attract experienced executives.
But critics see a deeper issue.
When healthcare organizations—whether nonprofit or for-profit—tie executive compensation to growth, expansion, and financial performance, the incentives begin to resemble those of any other large business. Decisions may increasingly prioritize revenue generation, market share, and operational efficiency rather than patient outcomes.
This does not mean nonprofit hospitals fail to provide important services. Many do offer charity care, research programs, and community health initiatives.
But the growing scale and corporate structure of these institutions illustrate a broader reality: modern healthcare has become deeply intertwined with business incentives.
And nowhere is that connection between profit and medicine more visible than in the pharmaceutical industry.
Pharma: Why Americans Pay the Highest Drug Prices in the World
Paying More for the Exact Same Medicines
The pharmaceutical industry is often portrayed as one of the most innovative sectors in modern medicine. Drug companies invest billions of dollars in research and development to create new treatments for cancer, chronic disease, and life-threatening conditions.
But when it comes to drug prices, the United States stands apart from the rest of the world.
The US accounts for roughly 44% of the global pharmaceutical market, representing more than $600 billion in annual spending. On a per-person basis, Americans spend significantly more on prescription drugs than citizens of any other developed country.
What makes this even more striking is that Americans are not receiving different or superior medicines.
In many cases, they are purchasing the exact same drugs available in other countries, but paying dramatically higher prices for them.
Studies comparing popular medications across developed nations repeatedly find that the United States pays far more for identical treatments—even after accounting for discounts.
One striking example is the leukemia drug Gleevec, which has been reported to cost tens of thousands of dollars more per year in the United States than in many other countries.
And the variation does not just occur between countries.
Even within the United States, patients may pay wildly different prices for the same medication depending on their insurance plan, location, or pharmacy. Some medications can have thousands of different prices across insurance networks, creating a confusing and opaque pricing system that few patients fully understand.
The Medicare Noninterference Clause
One of the key reasons drug prices are so high in the United States lies in how pharmaceutical pricing is negotiated.
In most developed countries, national governments negotiate directly with pharmaceutical companies to determine the prices that public healthcare systems will pay for medications. Because the government represents millions of patients, it has enormous bargaining power.
The United States, however, operates very differently.
For many years, federal law included a provision known as the Medicare Noninterference Clause, which prevented the government from directly negotiating drug prices for Medicare recipients.
Instead of a single large negotiator representing the entire population, negotiations were fragmented across many private insurers and pharmacy benefit managers.
This fragmentation dramatically weakens the bargaining power of buyers.
Pharmaceutical companies are able to set higher prices because they are negotiating with multiple smaller purchasers rather than one massive national buyer.
The result is predictable: Americans pay far more for prescription drugs than patients in other developed countries.
Fragmented Negotiation Power in Drug Pricing
Another policy that contributed to pricing complexity is the Medicaid Drug Rebate Program, which established specific rebate requirements for drugs purchased through Medicaid.
While the program helped limit costs within Medicaid itself, it also had unintended consequences.
Pharmaceutical companies responded by adjusting pricing strategies across the broader market to compensate for the revenue lost through mandatory rebates. In other words, price controls in one part of the system were often offset by higher prices elsewhere.
Combined with fragmented negotiations, this dynamic allows pharmaceutical companies to maintain strong pricing power in the United States.
The result is a healthcare system where patients frequently face extremely high drug costs—even for medications that have existed for years and are widely used around the world.
But pricing is not the only ethical concern surrounding the pharmaceutical industry.
The relationship between drug companies and the doctors who prescribe their products introduces another layer of complexity—and controversy.
The Ethical Gray Zone Between Pharma and Doctors
Financial Relationships and Prescription Influence
At the center of modern medicine sits a crucial decision-maker: the physician.
Doctors determine which medications patients receive, which treatments they pursue, and which pharmaceutical products ultimately succeed in the marketplace. Because of this influence, pharmaceutical companies have a powerful incentive to build relationships with the doctors who prescribe their drugs.
In principle, collaboration between doctors and pharmaceutical companies can be beneficial. Physicians often contribute to clinical trials, provide expert guidance on drug development, and help translate scientific discoveries into practical medical treatments.
But the relationship between these two groups has long raised ethical concerns.
When pharmaceutical companies financially compensate doctors through speaking engagements, consulting arrangements, research funding, or other payments, critics argue that it can blur the line between medical judgment and commercial influence.
Even if physicians believe they remain objective, financial ties may still create subtle pressures that affect prescribing behavior.
The Growing Scale of Pharma Payments
In response to concerns about these relationships, the United States introduced the Open Payments Database in 2014. This program requires pharmaceutical and medical device companies to disclose financial payments made to physicians and teaching hospitals.
The goal was transparency—allowing patients, regulators, and researchers to see how much money was flowing between drug companies and healthcare providers.
What the data revealed was striking.
Since the program began, payments from pharmaceutical companies to healthcare professionals have grown dramatically. The total value of these payments has increased from roughly $6.5 billion in 2014 to nearly $13 billion in recent years.
Not all of these payments are illegal or inappropriate. Many involve legitimate activities such as clinical research, medical education, or advisory roles.
However, the sheer scale of the financial relationships raises difficult questions.
When doctors receive significant funding from pharmaceutical companies, patients may reasonably wonder whether prescribing decisions are influenced—even unintentionally—by those financial connections.
When Medical Decisions Become Financially Complicated
The healthcare industry has seen numerous cases where pharmaceutical companies crossed ethical and legal lines in their efforts to promote specific drugs.
Over the years, several major pharmaceutical firms—including companies like Novartis, Pfizer, and Purdue Pharma—have faced investigations or legal action related to marketing practices, kickbacks, or misleading promotion of medications.
The most infamous example in recent history is the opioid crisis, where aggressive marketing and financial incentives contributed to widespread overprescription of powerful painkillers.
The consequences of these practices were devastating, contributing to one of the most severe public health crises in modern American history.
Even outside such extreme cases, the close relationship between pharmaceutical companies and healthcare providers creates a complicated ethical landscape.
Patients depend on doctors to make treatment decisions based solely on medical evidence and patient needs. But when the same doctors operate within a system where billions of dollars flow between pharmaceutical companies and medical professionals, maintaining that independence becomes more challenging.
Taken together, the insurance system, healthcare providers, and pharmaceutical industry reveal a common theme.
Each sector operates according to its own economic incentives—and those incentives do not always align with the health and well-being of patients.
Yet despite all of these systemic problems, the American healthcare system still possesses some remarkable strengths.
A System That Works Brilliantly—If You Can Afford It
The Technology and Talent of American Medicine
Despite its many structural problems, the American healthcare system possesses capabilities that are unmatched in many parts of the world.
The United States is home to some of the most advanced hospitals, research institutions, and medical technologies ever developed. Many of the world’s leading medical schools, cutting-edge treatment centers, and groundbreaking pharmaceutical innovations originate in the US.
American hospitals often lead the world in complex procedures, experimental treatments, and specialized care. The country attracts some of the best-trained physicians, surgeons, and medical researchers anywhere on the planet.
For patients with access to elite medical institutions—and the financial means to pay for them—the quality of care can be extraordinary.
In fields such as oncology, surgery, biotechnology, and advanced diagnostics, the US frequently sits at the forefront of global medical innovation.
The Luxury Model of Healthcare
But this level of medical excellence comes with a critical caveat.
Access to the best care in the United States is often tied directly to financial resources and insurance coverage.
In many ways, the American healthcare system resembles a luxury product. It offers world-class capabilities, but only for those who can afford the price.
The system has been compared to owning a high-performance sports car—something like a Lamborghini. It can deliver incredible performance under the right conditions, but it is expensive to maintain and inaccessible to many people.
Most societies would find it absurd if the only cars available were luxury vehicles.
Yet in healthcare, that is essentially the structure the United States has built: a system capable of extraordinary results, but priced in a way that excludes many from accessing those benefits.
Why Cost Determines Access
The consequence of this structure is that access to healthcare often becomes a function of income, insurance status, and employment.
Individuals with strong employer-sponsored insurance plans or significant personal wealth can navigate the system relatively easily. They gain access to top-tier hospitals, advanced treatments, and specialists.
But for millions of other Americans, the experience is very different.
High deductibles, coverage limitations, prior authorization requirements, and surprise medical bills create barriers that can delay or prevent care altogether.
This divide creates a strange paradox.
The United States may have some of the best healthcare in the world, but it also has a system where many people struggle to access even basic medical services.
In other words, the American healthcare system is not universally broken.
It works extremely well—for those who can afford it.
But when a system responsible for life-and-death care functions primarily as a luxury good, the question becomes unavoidable:
Is this really the best way to deliver healthcare in a modern society?
The answer to that question brings us to the broader conclusion about why the American healthcare system continues to struggle.
Conclusion
The American healthcare system is often described as complicated, inefficient, or expensive. But those words alone fail to capture the deeper problem.
The system is not broken because of a single bad policy or one greedy industry. It is broken because every major part of the system operates under incentives that prioritize financial outcomes over health outcomes.
Insurance companies profit when they limit payouts. Hospitals and healthcare groups benefit when they consolidate market power and increase prices. Physician supply constraints push salaries higher while limiting access to care. Pharmaceutical companies maximize profits by charging the highest prices the market will tolerate. Even nonprofit institutions increasingly operate with corporate-style incentives.
Individually, each actor behaves rationally within the rules of the system.
Collectively, those incentives produce a healthcare structure that is extraordinarily expensive, administratively complex, and often inaccessible to the people who need it most.
This is why the United States finds itself in a strange position. It spends more on healthcare than any country in the world, yet consistently ranks near the bottom among developed nations in access, affordability, and outcomes.
At the same time, the system contains some of the most advanced hospitals, technologies, and medical professionals anywhere on Earth. For patients who can afford it, American healthcare can deliver extraordinary care.
But healthcare is not like buying a luxury car or choosing a premium airline seat.
It is a system responsible for human life, dignity, and survival. When access to care depends primarily on financial resources rather than medical need, the consequences extend far beyond economics.
The uncomfortable reality is that the American healthcare system is not failing by accident. It is producing exactly the results its incentives were designed to create.
Until those incentives change, the United States will likely continue paying more for healthcare than anyone else—while struggling to deliver the outcomes its citizens deserve.